ClinicalTrials.gg
CompletedNCT03270501GO-GUTUpdated Feb 11, 2025Results posted

Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation

A Phase 3 interventional study of Golimumab in Axial Spondyloarthritis, sponsored by University Ghent. Completed at 3 sites in Belgium. Open to participants aged 18 Years to 46 Years. Per ClinicalTrials.gov, last updated 2025-02-11.

Sponsored by University Ghent · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
64
Allocation
Not applicable
Ages
18 Years to 46 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 17 studies in Axial Spondyloarthritis with a site in Belgium — 1 open to participants now, 2 under way, 1 of them phase 3. Axial Spondyloarthritis · Belgium.

Enrollment
13th of 13
64 · median 383
Started
2017
with 1 other
Phase 3
12 of 17
none open now
Registered
8th of 17
by date

Among the 17 studies in Axial Spondyloarthritis with a site in Belgium, this one is the 13th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2017, is one of 12 in phase 3, and was the 8th registered.

Axial Spondyloarthritis

187 studies on the registry are indexed under Axial Spondyloarthritis; 57 are open to participants now.

Browse Axial Spondyloarthritis studies →

Open to participants now

1 of the 17 studies in Axial Spondyloarthritis with a site in Belgium is open now. Recruiting first, the newest first:

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 38 Axial Spondyloarthritis studies recruiting now, 20 (53%) set no upper age limit and 12 (32%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 46 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Axial Spondyloarthritis with a site in Belgium, or all of them as a file.
02

Study summary

The hypothesis of the study is that the presence of (subclinical) gut inflammation at baseline in patients with early active axial spondyloarthritis predisposes to a more severe disease defined as more need to use anti-tumor necrosis factor α therapy and a shorter time to relapse after stopping anti-tumor necrosis factor α therapy after obtaining sustained clinical remission. Overall, the investigators hypothesize that subclinical gut inflammation is an important predictor in therapy response and outcome. These data could provide better insights into the complex interactions between gut and joint inflammation and guide the physicians in the therapeutic approach.

03

Conditions studied

  • Axial Spondyloarthritis
04

Who can participate

Ages eligible
18 Years to 46 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must have a diagnosis of axSpA and classified according to ASAS criteria.
  • Subject has at least 3 months and maximum 1 year (almost) daily chronic back pain.
  • Subject has an active disease defined as a positive MRI (according to ASAS definition) or elevated CRP (in patients who are HLA-B27+) and an ASDAS score > 2.1 (at least high disease activity).

Exclusion criteria

Exclusion Criteria:

  • Full anti-inflammatory dose of NSAIDs for more than 4 weeks for the duration of the axSpA symptoms.
  • Prior exposure to any biologic therapy with a potential therapeutic impact on SpA, including anti-TNF therapy.
  • Exposure to disease-modifying drugs (DMARDSs; i.e. methotrexate and sulfasalazine) in the last 3 months before the ileocolonoscopy.
  • Exposure to systemic treatment in the last 14 days before the ileocolonoscopy.
  • Infection(s) requiring treatment with intravenous antibiotics/antivirals/antifungals within 30 days prior to the baseline visit or oral antibiotics/antivirals/antifungals within 14 days prior to the baseline visit.
  • Have a known to human immunoglobulin proteins or other components of golimumab.
  • History of central nervous system (CNS) demyelinating disease or neurologic symptoms suggestive of CNS demyelinating disease.
  • History of listeriosis, histoplasmosis, chronic of active infection, infection, (HIV) infection, immunodeficiency syndrome, chronic recurring infections or active tuberculosis.
  • Have a history of, or concurrent, chronic heart failure, including medically controlled, asymptomatic congestive heart failure.
  • Evidence of dysplasia or history of (including lymphoma and leukemia) other than a successfully treated non- cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of the cervix.
  • Have received, or are expected to receive, any live virus or bacterial vaccination within 3 months prior to the first administration of study agent, during the trial, or within 6 months after the last administration of study agent.
  • Positive pregnancy test at screening.
  • Female subjects who are breast-feeding or considering becoming pregnant during the study.
  • Female subjects who do not use .
  • History of drug or alcohol abuse in the last 12 months.
  • Clinically significant abnormal screening laboratory results as evaluated by the investigator.
  • Positive rheumatoid factor (RF) or anti-cyclic citrullinated peptide (anti-CCP) antibody at screening if the titers are crossing 3 times the .
  • Subject with diagnosis and current symptoms of fibromyalgia.
  • Any medical or psychological condition that, in the opinion of the investigator, could jeopardize or compromise the subject's ability to participate in this study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Arm 1: Golimumab

    Drug: Golimumab

Interventions

  • Axial spondyloarthritis patients who don't have a good treatment response on 2 NSAIDs, will be treated with golimumab. After remission, the therapy will be stopped. All patients will undergo a ileocoloscopy at baseline and, if positive, at time of remission.

    Also known as: ileocoloscopy

06

What researchers measure

Primary outcomes

  1. Proportion of Patients Achieving Sustained Clinical Remission

    The proportion of patients who completed the trial and achieved Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) \< 1.3 recorded on 2 consecutive visits with at least 12 weeks interval. ASDAS-CRP was measured at every study visit, i.e. baseline, week 2, week 4, week 16, week 28, week 40 and week 52. The study endpoint could earliest be achieved at visit week 28.

    Time frame: Upon end of trial for individual patient, between 28 and 52 weeks.

Secondary outcomes

  1. The Proportion of Patients With Healed Lesions of the Intestinal Mucosa

    According to the protocol, every patient underwent ileocolonoscopy at baseline to screen for macroscopic and microscopic (histopathologic analysis of endoscopic biopsies) signs of inflammation. If baseline ileocolonoscopy was protocolled as positive, the patient would undergo a second ileocolonoscopic assessment at the timepoint of reaching sustained clinical remission (study endpoint). The outcome measure is the proportion of patients with a negative second ileocolonoscopy.

    Time frame: At reaching primary outcome (between week 24 and week 52)

07

Results

Posted Feb 11, 2025
Limitations and caveats
The trial included 64 of initially anticipated 147 patients, which impacts downstream analyses which were powered for a larger group. The baseline prevalence of gut inflammation in the studied patient population was lower than anticipated. Therefore primary objective of the study (to evaluate whether there is a higher need of anti-TNFα treatment in patients with gut inflammation compared to those without) could not be adressed.

Participant flow

Recruitment period: November 2017 - December 2022 across 3 centres: * Gent University Hospital * Imelda Hospital in Bonheiden * Jessa Hospital in Hasselt

Participant flow — Overall Study
MilestoneArm 1: NSAIDs With Possible Step-up to Golimumab
Started64
Treatment protocol initiated58
Completed55
Not completed9
Withdrew: Screen failure6
Withdrew: Lost to follow-up2
Withdrew: Adverse event1

Outcome measures

PrimaryProportion of Patients Achieving Sustained Clinical Remission

The proportion of patients who completed the trial and achieved Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP) \< 1.3 recorded on 2 consecutive visits with at least 12 weeks interval. ASDAS-CRP was measured at every study visit, i.e. baseline, week 2, week 4, week 16, week 28, week 40 and week 52. The study endpoint could earliest be achieved at visit week 28.

Time frame:
Upon end of trial for individual patient, between 28 and 52 weeks.
Reported as:
Count of participants · Participants
Proportion of Patients Achieving Sustained Clinical Remission
ParticipantsArm 1: NSAIDs With Possible Step-up to Golimumab
Proportion of Patients Achieving Sustained Clinical Remission34
SecondaryThe Proportion of Patients With Healed Lesions of the Intestinal Mucosa

According to the protocol, every patient underwent ileocolonoscopy at baseline to screen for macroscopic and microscopic (histopathologic analysis of endoscopic biopsies) signs of inflammation. If baseline ileocolonoscopy was protocolled as positive, the patient would undergo a second ileocolonoscopic assessment at the timepoint of reaching sustained clinical remission (study endpoint). The outcome measure is the proportion of patients with a negative second ileocolonoscopy.

Time frame:
At reaching primary outcome (between week 24 and week 52)
Reported as:
Count of participants · Participants
The Proportion of Patients With Healed Lesions of the Intestinal Mucosa
ParticipantsArm 1: NSAIDs With Possible Step-up to Golimumab
The Proportion of Patients With Healed Lesions of the Intestinal Mucosa0

Adverse events

Collected over Adverse events data was collected between the first dose administration of trial medication and the last trial related activity (through study completion, between 24 weeks and 52 weeks). Medical events that occurred between signing of the Informed Consent and the first intake of trial medication were documented as medical and surgical history section and concomitant diseases.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1: NSAIDs With Possible Step-up to Golimumab0/58 (0%)0/58 (0%)19/58 (32.8%)
Most frequent other events
Most frequent other events
EventArm 1: NSAIDs With Possible Step-up to Golimumab
NasopharyngitisInfections and infestations14/58
GastroenteritisInfections and infestations4/58
OtitisInfections and infestations3/58

Baseline characteristics

Patients included in the trial and for whom the treatment protocol was initiated.

Age, Continuous
Age, Continuous(years)Arm 1: NSAIDs With Possible Step-up to Golimumab
Mean28.2 ± 6.3
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1: NSAIDs With Possible Step-up to Golimumab
Female24
Male34
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1: NSAIDs With Possible Step-up to Golimumab
Hispanic or Latino0
Not Hispanic or Latino56
Unknown or Not Reported2
Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP
Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP(units on a scale)Arm 1: NSAIDs With Possible Step-up to Golimumab
Mean3.0 ± 0.9
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)(units on a scale)Arm 1: NSAIDs With Possible Step-up to Golimumab
Mean4.5 ± 1.5
Bath Ankylosing Spondylitis Functional index (BASFI)
Bath Ankylosing Spondylitis Functional index (BASFI)(units on a scale)Arm 1: NSAIDs With Possible Step-up to Golimumab
Mean3.0 ± 2.2
Positive for HLA-B27 (%)
Positive for HLA-B27 (%)(Participants)Arm 1: NSAIDs With Possible Step-up to Golimumab
Count of participants50
Body mass index (BMI)
Body mass index (BMI)(kg/m^2)Arm 1: NSAIDs With Possible Step-up to Golimumab
Mean23.3 ± 4.7

12 further baseline measures are reported on the registry.

08

Study locations

3 sites
  • Imelda Bonheiden
    Bonheiden, Antwerpen 2820, Belgium
  • Ghent University Hospital
    Ghent, B - Belgium 9000, Belgium
  • Reuma Instituut Hasselt
    Hasselt, Limburg 3500, Belgium
09

References and documents

Publications

  • Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011 Jun 18;377(9783):2127-37. doi: 10.1016/S0140-6736(11)60071-8. PubMed 21684383 ↗
  • Mielants H, Veys EM, Cuvelier C, De Vos M, Botelberghe L. HLA-B27 related arthritis and bowel inflammation. Part 2. Ileocolonoscopy and bowel histology in patients with HLA-B27 related arthritis. J Rheumatol. 1985 Apr;12(2):294-8. PubMed 3875721 ↗
  • Van Praet L, Van den Bosch FE, Jacques P, Carron P, Jans L, Colman R, Glorieus E, Peeters H, Mielants H, De Vos M, Cuvelier C, Elewaut D. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis. 2013 Mar;72(3):414-7. doi: 10.1136/annrheumdis-2012-202135. Epub 2012 Nov 8. PubMed 23139267 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Dec 2023, 73 months.

Results were first posted in Feb 2025, 1 year 1 month after primary completion.

Of 20 phase 3 interventional studies under Axial Spondyloarthritis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 39. This study's 73 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2017
First posted
Sep 1, 2017
StartActual
Nov 8, 2017
Primary completionActual
Dec 14, 2023
CompletionActual
Dec 14, 2023
Results first posted
Feb 11, 2025
Last update
Feb 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03270501
Lead sponsor
University Ghent
Collaborators
Merck Sharp & Dohme LLC, the Flanders Institute for Biotechnology
Responsible party
Sponsor
First posted
Sep 1, 2017
Start date
Nov 8, 2017
Primary completion
Dec 14, 2023
Completion
Dec 14, 2023
Results posted
Feb 11, 2025
Last update
Feb 11, 2025

Study contacts

Dirk Elewaut
principal investigator · University Ghent

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Golimumab

Start the discussion